Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine

Fig. 1

Decitabine dose-dependently suppresses AML cell proliferation in vitro. A Viability of three cell lines after treatment with decitabine at different concentrations for 72 h. B Viability of three cell lines after treatment with 500 nM decitabine for different times. C Western blot analysis of cells treated with decitabine. D The cells apoptosis after treatment with decitabine (*P < 0.05 using ANOVA)

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us